
Home » SEPRACOR DOUBLES Q1 REVENUE, TURNS PROFIT
SEPRACOR DOUBLES Q1 REVENUE, TURNS PROFIT
April 25, 2006
Sepracor Inc. driven by booming sales of its anti-insomnia drug Lunesta turned a profit in its fiscal 2006 first quarter and more than doubled revenue compared to the same period last year. The Marlborough, Mass., pharmaceutical company (Nasdaq: SEPR) reported $285.7 million in revenue for the quarter ending March 31, compared to $119 million in revenue in the fiscal 2005 first quarter, just before Lunesta sales launched.
Boston Business Journal
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr